Characteristics of serum hyaluronate concentrations in patients with alcoholic liver disease.
It has been reported that serum hyaluronate [hyaluronic acid (HA)] concentrations are increased in liver diseases, especially in alcoholic liver disease (ALD). However, the characteristics of serum HA concentration in patients with ALD have not been studied. In this study, first, we measured serum HA concentrations in patients with different stages of both ALD and non-ALD to clarify the characteristics of serum HA concentration in patients with ALD. Second, we measured serum HA concentrations in patients with ALD sequentially after abstinence. We also measured serum HA concentrations in patients with chronic type C hepatitis before and after treatment with interferon. Finally, we analyzed the relationship between serum HA concentrations and the contents of type IV collagen and laminin in the livers of both ALD and non-ALD patients. Serum HA concentrations in liver disease were higher than the cut-off value, and increased significantly (p < 0.001) in parallel with the progression of hepatic fibrosis in both ALD and non-ALD patients. Serum HA concentrations in patients actively drinking with ALD were significantly higher (p < 0.001) than those in non-ALD. After 4 weeks of abstinence, these concentrations fell to the levels of non-ALD. Although serum ALT levels were decreased in 80% of patients treated with interferon, serum HA concentrations were not changed or increased. A significant correlation between serum HA concentrations and hepatic type IV collagen and laminin content was present in ALD, but not in non-ALD. These results clearly suggest that the increase of serum HA concentrations in ALD may be associated with not only hepatic fibrosis, but also alcohol drinking.
Tsutsumi
M
M
Department of Internal Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Urashima
S
S
Takase
S
S
Ueshima
Y
Y
Tsuchishima
M
M
Shimanaka
K
K
Kawahara
H
H
D000428:Alcohol Drinking / Q000097:blood; D002908:Chronic Disease; D003094:Collagen / Q000032:analysis; D003937:Diagnosis, Differential; D018450:Disease Progression; D006526:Hepatitis C / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood* / Q000737:chemistry; D007372:Interferons / Q000627:therapeutic use; D007797:Laminin / Q000032:analysis; D008099:Liver / Q000737:chemistry; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis; D008108:Liver Diseases, Alcoholic / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D013695:Temperance
D007797:Laminin; D006820:Hyaluronic Acid; D003094:Collagen; D007372:Interferons